TGFB1 and neoplasm: For instance, Sorafenib has been found to exhibit anti-tumor activities by reducing the level of TGF-β secreted by TAMs, thereby inhibiting liver cancer growth, metastasis, and EMT (epithelial-mesenchymal transition) (Fridlender et al., 2009; Wei et al., 2015).